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Abstract
Background: We have previously shown that nuclear factor (NF)-B activation of mouse Lewis lung carcinoma
(LLC) specifically promotes the induction of malignant pleural effusions (MPE) by these cells. In the present studies
we hypothesized that treatment of immunocompetent mice with bortezomib tailored to inhibit cancer cell NF-B
activation and not proliferation specifically inhibits MPE formation by LLC cells.
Results: Treatment of LLC cells with low concentrations of bortezomib (100 ng/ml) inhibited NF-B activation and
NF-B-dependent transcription, but not cellular proliferation. Bortezomib treatment of immunocompetent C57BL/6
mice bearing LLC-induced subcutaneous tumors and MPEs significantly blocked tumor-specific NF-B activation.
However, bortezomib treatment did not impair subcutaneous LLC tumor growth, but was effective in limiting LLC-
induced MPE. This specific effect was evidenced by significant reductions in effusion accumulation and the
associated mortality and was observed with both preventive (beginning before MPE formation) and therapeutic
(beginning after MPE establishment) bortezomib treatment. The favorable impact of bortezomib on MPE was
associated with suppression of cardinal MPE-associated phenomena, such as inflammation, vascular
hyperpermeability, and angiogenesis. In this regard, therapeutic bortezomib treatment had identical favorable
results on MPE compared with preventive treatment, indicating that the drug specifically counteracts effusion
formation.
Conclusions: These studies indicate that proteasome inhibition tailored to block NF-B activation of lung
adenocarcinoma specifically targets the effusion-inducing phenotype of this tumor. Although the drug has limited
activity against advanced solid lung cancer, it may prove beneficial for patients with MPE.
Background
A malignant pleural effusion (MPE) affects one in seven
patients with cancer, most commonly lung or breast
adenocarcinoma [1,2]. For these patients, MPE has
severe consequences: it prohibits surgical cure and por-
tends short and cumbersome survival [3]. Current treat-
ments against MPE (pleural evacuation or pleurodesis)
[1,2,4,5] are associated with hospital stay, interventional
procedures, morbidity and mortality, and benefit only
select patients [1-8]. Towards improving current prac-
tice against MPE, a better understanding of its patho-
genesis is required, which may aid in developing
effective strategies to block pleural fluid accumulation in
patients with cancer.
The pathogenesis of MPE was unclear, mainly due to
the lack of relevant animal models [9-11]. Using a proto-
type immune-competent mouse model, we described
that activation of nuclear factor (NF)-Bi nl u n ga d e n o -
carcinoma specifically facilitates MPE, but not the growth
or metastasis of this neoplasm [12,13]. We found that
this effect of NF-B on MPE formation was not mediated
via enhanced tumor growth, but by enhanced expression
of NF-B-dependent gene products, including tumor
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(CCL) 2 [14,15]. We furthermore determined that this
MPE-inducing phenotype of lung adenocarcinoma is not
ubiquitous to all tumor types and involves specific MPE-
associated phenomena such as inflammation, angiogen-
esis, and leakiness of pleural blood vessels [12-15]. These
studies identified NF-B as a promising therapeutic tar-
get in lung adenocarcinoma-induced MPE.
Various approaches have been tailored to block NF-B
in cancer cells, since the transcription factor has emerged
as a promoter of inflammation-associated cancers
[16-18]. These include blockade of inhibitor of NF-B
(IB) kinases (IKK) [19] and proteasome inhibition,
which suppresses NF-B by diminishing IB degradation
[20]. Although the latter approach is less specific, the
proteasome inhibitor bortezomib blocks NF-B in a vari-
ety of cells and is already in clinical use against multiple
myeloma [20-22]. Unfortunately, the initial optimism
regarding activity of the drug against non small-cell lung
cancer (NSCLC) [23] that led to several completed/
ongoing phase I/II trials was recently hampered by the
results of these trials reporting limited or no single-agent
activity of bortezomib against advanced NSCLC [24,25].
In the present studies we hypothesized that bortezomib
treatment tailored to inhibit NF-B activation of Lewis
lung cancer (LLC) is specifically effective in limiting MPE,
but not solid tumor formation by this neoplasm. We
tested our hypothesis by titrating the effects of bortezomib
on LLC cell NF-B activation and proliferation and by
conducting parallel experiments of intrapleural and subcu-
taneous introduction of this tumor into syngeneic mice.
Methods
Reagents
Bortezomib (Millenium, Cambridge, MA) was purchased
from the pharmacy, D-luciferin from Biosynth AG
(Naperville, IL), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carbox-
ymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) assay, passive lysis buffer, and firefly
luciferase assay system fromP r o m e g a( M a d i s o n ,W I ) ,
recombinant human (rh) TNF from Peprotech (London,
UK), ELISA from Peprotech (London, UK) and R&D
Systems (Minneapolis, MN), anti-proliferating cell
nuclear antigen (PCNA) antibody from SantaCruz Bio-
technology (Santa Cruz, CA), terminal deoxynucleotidyl
nick-end labeling (TUNEL) kit from Roche (Penzberg,
Germany), anti-factor VIII-associated protein (F8A) anti-
body from Invitrogen (San Francisco, CA), and Evans’
blue from Sigma (St Louis, MO).
Cell experiments
LLC mouse lung adenocarcinoma cells were purchased
from the American Type Culture Collection (Manassas,
VA; identifier: CRL-1642), were verified by antigen H-2b
expression, and were stored at -80°C, resuscitated, and
cultured at 37°C in 5% CO2-95% air using DMEM 10%
FCS supplemented with glutamine and 100 mg/l penicil-
lin/streptomycin. Wild-type or pNGL LLC cells stably
expressing a NF-Br e p o r t e r( N F - B. GFP.LUC; pNGL)
[12-14] were plated at equal densities in 6- or 96-well
culture dishes till 20-30% confluent and were incubated
with PBS or 1 nM rhTNF, in the presence of varying
concentrations of bortezomib. Luciferase activity was
determined after four hours by luciferase assay and bio-
luminescent imaging, as described below. Cell viability
and mediator elaboration into culture media were deter-
mined after 24 hours, using MTS reduction capacity
and ELISA, respectively. All cell experiments were done
in triplicate.
Determination of luciferase bioactivity
Luciferase activity of whole cells or tissue homogenized
in passive lysis buffer (Promega, Madison, WI) was
determined using a “Junior” luminometer (EG&G Bert-
hold, Bad Wildbad, Germany), after addition of 100 μl
firefly luciferase assay system to 20 μl sample, as
described previously [14]. Luciferase activity was cor-
rected for total protein, determined using the Bio-Rad
assay (Hercules, CA). Serial bioluminescence imaging of
live mice bearing pNGL LLC-induced subcutaneous
tumors or MPE was done using intravenous injection of
1 mg D-luciferin, and of cultured pNGL LLC cells four
hours after treatment application using addition of 10
mM D-luciferin [12,13]. Imaging was performed using
the Xenogen IVIS cooled CCD (Xenogen, Alameda,
CA). Data were analyzed using Living Image v.2.50
(Xenogen) and IgorPro (Wavemetrics, Lake Oswego,
OR) [12,13].
Cytokine determinations
Mouse TNF, C-X-C motif chemokine ligand (CXCL) 1,
CXCL2, and CCL2 (detection limits: 5.1, 7.8, 1.5, and
15.6 pg/ml, respectively) expression levels were deter-
mined using ELISA and were corrected for total protein.
Animal Models
C57BL/6 mice were purchased from the Hellenic Pasteur
Institute (Athens, Greece) and the Jackson Laboratory
(Bar Harbor, ME) and inbred at the Animal Care facilities
of the General Hospital Evangelismos (Athens, Greece)
and of Vanderbilt University. Animal care and experi-
ments were approved by the Veterinary Administration,
Prefecture of Athens, Greece, and the Institutional Ani-
mal Care and Use Committee at Vanderbilt University
and were conducted according to international standards
http://grants.nih.gov/grants/olaw/GuideBook.pdf. Experi-
mental mice were sex-, weight (19-24 g)-, and age (8-10
week)-matched. Solid adenocarcinomas and MPEs were
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pNGL LLC cells in the flank (5 × 10
5 cells) or pleural
space (1.5 × 10
5 cells). In mice with subcutaneous LLC
tumors, three vertical tumor dimensions (δ1, δ2, δ3) were
measured weekly, and tumor volume (V) was determined
using the formula V = π ×( δ1×δ2×δ3)/6. In mice with
LLC-induced MPEs, sacrifice, necropsy, and specimen
(MPE, blood, tumor) collection were performed on day
14 as described previously [12-15,26].
In vivo bortezomib treatment
Mice with subcutaneous LLC tumors received bi-weekly
intraperitoneal bortezomib (100 ng/g = 0.1 mg/kg in
100 μl PBS) or 100 μlP B Sc o n t r o la td a y s2 ,5 ,9 ,1 2 ,
16, 19, 23, and 26 after tumor cell inoculation. Mice
that received intrapleural LLC cells were treated with
intraperitoneal bortezomib (100 ng/g = 0.1 mg/kg in
100 μlP B S )o r1 0 0μl PBS control starting either before
(bortezomib prevention trial; days 2, 5, 9, and 12 after
LLC cells), or after the onset of active fluid exudation
(bortezomib regression trial; days 9 and 12 after LLC
cells), which occurs at day 8 in the LLC-induced mouse
MPE model [12,26].
Histology & cytology
Tumors were fixed in 10% neutral buffered formalin (24
hours) and 70% ethanol (3 days). Tumors were dissected
and embedded in paraffin. 5-μm-thick sections were cut,
mounted on glass slides, and stained with hematoxylin &
eosin. Alternatively, tissue sections were immunostained
using antibodies for PCNA, TUNEL, and F8A, and
immune-labeling was quantified, as described previously
[12-15,26]. For cytocentrifugal specimen (cytospin) pre-
paration, 50000 pleural fluid cells were used. The slides
were air dried, fixed in methanol for 10 seconds, and
stained with May-Gruenwald-Giemsa. Distinct cell types
were enumerated as a percentage of 400 cells on the slide.
Pleural Permeability Assay
At day 14 post-LLC cells, mice bearing MPEs induced
by LLC cells received 200 μlo f4m g / m lE v a n s ’ blue
solution (0.8 mg) intravenously and were killed 1 hour
later. Pleural fluid Evans’ blue concentration was deter-
mined using absorbance at 605 nm, as described pre-
viously [12-15,26].
Statistics
All values are presented as mean ± standard error of
mean (SEM). Survival is given as median (95% confi-
dence interval) and was analyzed using Kaplan-Meier
estimates. Differences in the means between two or
multiple groups were examined using the Student’st -
test or one-way ANOVA with least square difference
post-hoc tests for normally distributed data, and the
Mann-Whitney u-test or Kruskal-Walis test with Mann-
Whitney u-post-hoc tests for not normally distributed
data. Differences in survival were assessed by log-rank
test. All P values are two-tailed; P values < 0.05 were
considered significant. All statistical analyses were per-
formed using the Statistical Package for the Social
Sciences v.13.0.0 (SPSS, Chicago, IL).
Results
Tailoring proteasome inhibition to block NF-B activation
of lung adenocarcinoma in vitro and in vivo
Initially we sought to titrate the effects of bortezomib
treatment on cellular proliferation and NF-B activation
of LLC cells in vitro. LLC cell proliferation was not sup-
pressed by bortezomib alone, but only when high con-
centrations of the proteasome inhibitor were combined
with exposure to TNF (Figure 1A). Using a NF-B-
reporter (pNGL), we determined that bortezomib inhib-
ited constitutive and TNF-inducible NF-B activation of
LLC cells at much lower concentrations (100 ng/ml)
(Figures 1B,1C). At these low concentrations, bortezo-
mib also inhibited NF-B-dependent gene transcription,
as determined by TNF, CXCL1, CXCL2, and CCL2 ela-
boration (Figure 1D). These results indicated that low
concentrations of bortezomib can be used to limit
mouse lung adenocarcinoma NF-B activation without
affecting cellular proliferation and identified 100 ng/ml
as a suitable concentration for this purpose.
Based on the good bioavailability of bortezomib [27],
we extrapolated the above studies to in vivo experiments
of low-dose (100 ng/kg = 0.1 mg/kg) bortezomib treat-
ment of C57BL/6 mice bearing LLC-induced subcuta-
neous tumors or MPEs, aiming to block tumor cell NF-
B activation without affecting cell proliferation. To
monitor the effects of proteasome inhibition specifically
on tumor cell NF-B activation, we employed models of
subcutaneous or intrapleural delivery of NF-B-lucifer-
ase reporter (pNGL) LLC cells to wild-type C57BL/6
mice [12-14]. Following reporter cell injection, subcuta-
neous or intrapleural tumors were allowed one week to
form, and mice started receiving bi-weekly control or
bortezomib treatment on the second week of the experi-
ments. Tumor NF-B activation was monitored by serial
bioluminescence imaging and by luciferase activity
determinations in tumor tissues [12-14]. These studies
showed that this bortezomib regimen was effective in
suppressing tumor-specific NF-B activation of estab-
lished subcutaneous and pleural tumors (Figure 2).
Specific suppression of lung adenocarcinoma-induced
MPE formation but not tumor growth by NF-B-targeting
bortezomib treatment
We subsequently sought to assess the impact of NF-B-
tailored bortezomib treatment on LLC growth and MPE
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ments were repeated using injection of wild-type LLC
cells into the subcutaneous or pleural space of C57BL/6
mice. In accord with our hypothesis, treatment of
C57BL/6 mice bearing subcutaneous LLC tumors with
bi-weekly intraperitoneal bortezomib at 100 ng/g had no
effect on tumor growth compared with PBS control
treatment (Figures 3A,3B). In stark contrast, bortezo-
mib-treated mice bearing LLC-induced MPEs showed
significantly improved indices of MPE control, including
MPE volume and survival, compared with PBS-treated
mice with MPEs (Figures 3C-E). Importantly, preventive
administration of the drug (ie,s t a r t i n gp r i o rt oM P E
development) did not confer any additional protection
against MPE formation compared with therapeutic treat-
ment of MPE-bearing mice starting after MPE establish-
ment. These results indicated that our low-dose
proteasome inhibition regimen designed to block NF-B
activation of LLC lung adenocarcinoma had no effect on
the growth of this tumor in solid form, but was highly
effective against already established LLC-induced MPE
in mice.
Figure 1 Tailoring of bortezomib treatment to target nuclear factor (NF)-B activation of mouse lung adenocarcinoma cells in vitro. (A)
Relative MTS reduction capacity of Lewis lung cancer (LLC) cells after 24 hours of incubation with or without 1 nM recombinant human (rh) TNF
in the presence of varying concentrations of bortezomib. (B) Relative nuclear factor (NF)-B-dependent luciferase expression of NF-B. GFP.luc
(pNGL) LLC cells after 4 hours of incubation with or without 1 nM rh TNF in the presence of varying concentrations of bortezomib. (C)
Bioluminescence image of pNGL LLC cells exposed for 4 hours to the indicated doses of bortezomib. Colors on the top of the scale indicate
high light emission. (D) Cytokine/chemokine release by wild-type LLC cells incubated with or without 100 ng/ml bortezomib for 24 hours. TNF,
tumor necrosis factor; CXCL, C-X-C motif chemokine ligand; CCL, C-C motif chemokine ligand. All experiments were done thrice. Columns, dots,
mean; bars, standard error of mean. # and ###: P < .05 and .001, respectively, compared with cells treated with PBS. * and ***: P < .05 and .001,
respectively, compared with cells treated with 1 nM rhTNF.
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tumor growth suppression by NF-B-tailored bortezo-
mib treatment, we next assessed the proliferation and
apoptosis of tumor cells in vivo using PCNA and
TUNEL labeling, respectively (Figure 4). In both subcu-
taneous and pleural LLC-induced tumors, bortezomib
treatment had no effect on cell proliferation compared
with PBS control treatment. On the contrary, tumor cell
apoptosis rates were modestly but significantly increased
in both subcutaneous and pleural tumors from bortezo-
mib-treated mice, a finding consistent with the afore-
mentioned NF-B inhibitory effects of the employed
bortezomib regimen. These results confirmed that the
specific anti-MPE effects of NF-B-tailored proteasome
inhibition were not linked with tumor growth inhibition.
Moreover, the results of TUNEL suggested that the
anti-MPE effects of bortezomib-mediated NF-B
blockade could neither be ascribed to induction of
tumor cell apoptosis, since a pro-apoptotic response of
equal magnitude was observed in MPE-associated and
subcutaneous LLC tumors.
NF-B-tailored proteasome inhibition down-regulates
proinflammatory gene expression of pleural tumors and
cardinal MPE-associated phenomena
Based on the above results, we postulated that the speci-
fic effects of NF-B-targeted bortezomib treatment
against MPE are mediated via suppression of NF-B-
dependent gene expression, a hypothesis supported by
previous work of our group [12-15]. Indeed, TNF and
CXCL2 were decreased in MPEs from bortezomib-trea-
ted mice. In addition, TNF was down-regulated in the
blood from bortezomib-treated mice. However, all pro-
inflammatory NF-B-dependent mediators assayed were
Figure 2 Tailored bortezomib treatment inhibits tumor-specific nuclear factor (NF)-B activation of subcutaneous and intrapleural
lung adenocarcinoma. (A-C) NF-B-targeted bortezomib treatment blocks NF-B activation of subcutaneous adenocarcinoma in vivo. Wild-type
C57BL/6 mice received 5 × 10
5 subcutaneous NF-B-reporter (NF-B. GFP.luc, pNGL) Lewis lung carcinoma (LLC) cells and were allowed one
week for tumors to implant, where after they received bi-weekly intraperitoneal bortezomib (100 ng/g = 0.1 mg/kg) or PBS in a regression trial.
Mice were serially imaged for bioluminescence after intravenous injection of 1 mg D-luciferin at the time-points indicated (A, B) and were
sacrificed on day 21 for determination of NF-B-dependent luciferase bioactivity of tumor tissue homogenates (C). Shown are time course of
tumor-specific NF-B activity in flank tumors (A), representative bioluminescence images at day 21 (B), and summary of luciferase assay data
obtained at day 21 (C). (D-F) NF-B-targeted bortezomib treatment blocks NF-B activation of intrapleural adenocarcinoma in vivo. C57BL/6 mice
received 1.5 × 10
5 intrapleural pNGL LLC cells and were allowed one week, where after they received bi-weekly bortezomib (100 ng/g = 0.1 mg/
kg) or PBS. Mice were imaged for bioluminescence (D, E) and were sacrificed on day 14 for determination of NF-B-dependent luciferase
bioactivity of tumor tissue (F). Shown are time course of tumor-specific NF-B activity in MPE-bearing mice (D), representative bioluminescence
images at day 14 (E), and summary of luciferase assay data obtained at day 14 (F). n, sample size; RLU, relative light units. Dots, mean (left) or raw
data points (right); lines in panels on the right, mean; bars, standard error of mean. # and ###: P < .05 and .001, respectively, compared with
control.
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tezomib-treated mice compared with specimens
obtained from PBS-treated mice (Figure 5). The results
obtained from tumor tissue mirrored bortezomib-
induced suppression of the expression of these media-
tors by LLC cells in vitro (Figure 1B) and, in addition to
the TUNEL results described above, served as biomar-
kers of efficient in vivo suppression of NF-B activation
of mouse lung adenocarcinoma.
Finally, we examined the effects of NF-B-targeted bor-
tezomib treatment on inflammation, vascular hyperper-
meability, and new vessel formation, mechanisms central
in MPE formation that are profoundly influenced by the
tumor cells’ mediator expression profile [1,2,9-15,26].
Cytologic determinations revealed significantly reduced
numbers of neutrophils in MPE and blood from bortezo-
mib-treated mice, compared with controls (Figure 6A).
In addition, mononuclear cell numbers in MPEs from
bortezomib-treated mice were significantly lower
compared with controls. To determine vascular
hyperpermeability, separate sets of experimental mice
received 0.8 mg intravenous albumin-binding Evans’ blue
one hour before sacrifice (day 14). Evans’ blue leak from
the bloodstream into MPE was significantly lower in bor-
tezomib-treated mice compared with controls, indicating
reduction of albumin leakage (Figure 6B, left). An addi-
tional marker of pleural vascular permeability, the pleural
fluid/serum protein ratio [26], was also reduced by borte-
zomib treatment (Figure 6B, right). Finally, pleural tumor
tissue immune-labeling for the endothelial marker F8A
revealed significant reductions in microvessel density of
pleural tumors from bortezomib-treated mice (Figure
6C). Collectively, the above findings suggested that NF-
B-tailored proteasome inhibition in the mouse model of
adenocarcinoma-induced MPE suppresses the gene
expression of NF-B-dependent mediators in pleural
LLC tumors, which are required for the paracrine pro-
motion of inflammation, vascular leakiness, and angio-
genesis, the major known pathways for MPE induction
by cancer cells.
Figure 3 NF-B-targeted bortezomib treatment specifically inhibits MPE but not subcutaneous tumor formation by lung
adenocarcinoma. (A, B) NF-B-targeted bortezomib treatment has no effect on subcutaneous Lewis lung carcinoma (LLC) growth. C57BL/6
mice received 5 × 10
5 subcutaneous LLC cells followed by bi-weekly intraperitoneal bortezomib (100 ng/g = 0.1 mg/kg) or PBS. Separate subsets
of mice received treatment either immediately (prevention trial) or starting one week after tumor implant (regression trial). Tumor volume was
determined weekly and mice were sacrificed on day 28. Representative images at 4 weeks (A; dashed lines outline tumors) and mean volume (B)
of subcutaneous tumors in PBS and bortezomib treated mice. Results from prevention and regression trial were identical and were grouped for
demonstration purposes. Dots, mean; bars, standard error of mean. (C-E) NF-B-targeted bortezomib treatment is effective against malignant
pleural effusion (MPE) induced by LLC cells. C57BL/6 mice received 1.5 × 10
5 intrapleural LLC cells followed by bi-weekly bortezomib (100 ng/g
= 0.1 mg/kg) or PBS. Mice were enrolled in prevention (immediate treatment) or regression (treatment starting after one week) trials and were
sacrificed on day 14 (C, D) or observed till moribund (E). (C) Representative transdiaphragmatic photographs at 14 days (dashed lines outline
MPEs) and (D) mean volume of MPE in PBS- and bortezomib-treated mice. Dots, raw data points; lines, mean; bars, SEM. (E) Survival of MPE-
bearing mice treated with PBS or bortezomib. Shown are Kaplan-Meier survival curves and estimates (median, 95% confidence interval) of
pooled data from three independent experiments. (D, E) Note that results from prevention and regression trials were not significantly different
(ns). n, sample size; P, probability values. ## and ###: P < .01 and .001, respectively, compared with control.
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In the present studies we examined the effects of the
proteasome inhibitor bortezomib on NF-B-dependent
MPE induction by lung adenocarcinoma. By tailoring
drug treatment to specifically target NF-Ba c t i v a t i o n
and not cell proliferation of this tumor we achieved con-
sistent blockade of the transcription factor in cancer
cells in vitro and in vivo. Delivered in this fashion, the
proteasome inhibitor limited MPE formation by LLC
cells without impacting their subcutaneous growth rate.
In addition, therapeutic (eg, initiated before MPE forma-
tion) proteasome inhibition was equally effective in
achieving MPE control and in prolonging survival with
preventive treatment (eg, initiated after MPE establish-
ment), suggesting specific anti-MPE effects of NF-B-
targeted bortezomib treatment. Indeed, tailored
Figure 4 NF-B-targeted bortezomib treatment does not impact tumor cell proliferation in vivo. Subcutaneous (A, B) and pleural (C, D)
tumor tissue was obtained on days 28 and 14, respectively, from experiments described in Figure 3 and was immunostained for proliferating
cell nuclear antigen (PCNA; A, C) and terminal deoxynucleotidyl nick-end labeling (TUNEL; B, D), indicators of cell proliferation and apoptosis,
respectively. Shown are summary of results and representative photomicrographs (Å = 600; scale bars = 50 μm). NF-B-targeted bortezomib
treatment had no effect on Lewis lung carcinoma (LLC) cell proliferation in subcutaneous or pleural tumors (A, C). However, bortezomib
treatment resulted in enhanced apoptosis rates in both tumor sites (B, D). n, sample size; P, probability values; hpf, high-power field. Dots, raw
data points; lines, mean; bars, standard error of mean. #, ##, and ###: P < .05, .01, and .001, respectively, compared with control.
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B-dependent paracrine mediator expression of pleural lung
adenocarcinoma. Pleural fluid, blood, and pleural tumor tissue NF-
B-dependent gene product levels were determined in samples
obtained at day 14 from mice with MPE enrolled in control (n = 10),
bortezomib prevention (n = 10), and bortezomib regression (n = 7)
trials as in Figure 3C-D. TNF, tumor necrosis factor; CXCL, C-X-C
motif chemokine ligand; CCL, C-C motif chemokine ligand. Columns,
mean; bars, standard error of mean; n, sample size; P, overall
probability values. #, ## and ###: P < .05, .01, and .001, respectively,
compared with control.
Figure 6 NF-B-targeted bortezomib inhibits malignant pleural
effusion (MPE)-associated inflammation, vascular leakiness, and
angiogenesis. Mice were treated as in Figure 3C-D. (A) Pleural fluid
and blood inflammatory cell numbers at day 14. (B) Left: MPE Evans’
blue levels determined at day 14, one hour after intravenous
delivery of 0.8 mg of the dye. Right: MPE/serum protein ratio. Both
Evans’ blue leakage and protein ration are indicators of vascular
hyperpermeability. (C) Pleural tumor tissue microvessel density
assessed by immunoreactivity for factor VIII-associated protein (F8A).
Summary of data (left) and representative microphotographs (right;
Å = 400; scale bar = 100 μm; arrows, new vessels). MPE, malignant
pleural effusion; WBC, white blood cells; mono, mononuclear cells;
neu, neutrophils; hpf, high-power field. Columns, mean; bars,
standard error of mean; n, sample size; P, overall probability values.
#, ## and ###: P < .05, .01, and .001, respectively, compared with
control.
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gene expression of lung adenocarcinoma in vitro and in
vivo, resulting in down-regulation of all major paracrine
phenomena known to be involved in MPE formation:
inflammation, vascular hyperpermeability, and
neoangiogenesis.
This is the first preclinical study of the effects of any
NF-B or proteasome inhibitor on MPE. Our results
indicate that bortezomib is highly effective against
experimental MPE, favorably impacting all outcome
measures of MPE control. In addition, the drug was
effective even when given after the onset of active lung
adenocarcinoma-induced fluid exudation into the
pleural space, implying the potential for therapeutic use
against already established MPE. Human MPE is a sig-
nificant clinical problem, a fact reflected by the overt
insufficiency of current treatments [8] and by expert
recommendations for upgrading its prognostic signifi-
cance in the TNM staging system for NSCLC from a T4
to a M1a descriptor [28]. In face of the above, our find-
ings may prove clinically useful against human MPE.
In addition to their potential clinical utility, our results
yield insights into the determinants of site-specific lung
adenocarcinoma progression. In this regard, serosal
involvement and dissemination of this tumor appears to
be profoundly governed by a vicious triad of inflamma-
tion, vascular hyperpermeability, and new vessel forma-
tion, mechanisms that may be of lesser importance in
solid tumor progression, where stimulus-independent
tumor growth and evasion of apoptosis may be more
pivotal [29]. In this regard, the ability of tumor cells to
induce a MPE differs between various tumor types [15]
and may constitute an additional hallmark of adenocar-
cinoma. We show that this MPE-promoting phenotype
of lung adenocarcinoma, heavily dependent on NF-B-
controlled gene expression and not on NF-B-indepen-
dent tumor growth [12-15], can be selectively targeted
by tailored proteasome inhibition. The present and
other lines of evidence suggest that targeting host-tumor
interactions rather than tumor cell cycling may present
an effective future therapeutic strategy against cancer
[30]. Compared with their activity against solid tumors,
t h e s ea p p r o a c h e sm a yb em o r ee f f e c t i v ea g a i n s tM P E ,
which is largely governed by the paracrine effects of
tumor on the host immune system and vasculature
[2,9-15,26]. Indeed, in our hands tailored proteasome
inhibition specifically targeted lung adenocarcinoma-
induced MPE formation but not the growth of this
tumor in solid form. The specific anti-MPE effects of
bortezomib were also evident by the fact that it was
only effective when MPEs were present and preventive
administration provided no additional benefit over ther-
apeutic delivery. Although bortezomib enhanced apopto-
sis of pleural and subcutaneous tumors, this pro-
apoptotic effect was of minor magnitude. In addition,
bortezomib-induced apoptosis was observed in both
subcutaneous and pleural tumors, and thus did not pre-
sent a plausible explanation of the specific anti-MPE
effects of the drug. However, bortezomib treatment lim-
ited paracrine phenomena specifically linked with MPE
formation, such as angiogenesis, vascular hyperperme-
ability, and inflammation. Down-regulation of these
mechanisms via suppression of NF-B-dependent genes
in tumor cells may provide a more accurate mechanistic
insight into the anti-MPE functions of proteasome
inhibition.
Bortezomib has been tested against human NSCLC
and has been found to be ineffective [24,25]. However,
our results suggest that the drug may be worth testing
specifically against NSCLC-induced MPE. In this regard,
trials against NSCLC included a majority of patients
without MPE and a minority of patients with MPE
[24,25]. In addition, end-points related to MPE control
were not included in the design of these studies. Hence
a possible favorable effect of bortezomib treatment
against MPE may have gone undetected and, despite the
negative results of the aforementioned significant trials,
bortezomib may be still worth testing against human
MPE.
During the last few decades, knowledge of biologic
mechanisms of disease has expanded tremendously. How-
ever, therapeutic targeting of single disease culprits is lim-
ited by biologic diversity and redundancy, as well as cost
[31]. In this regard, simultaneous suppression of multiple
disease promoting pathways by small molecules would be
advantageous [26]. In our hands, a proteasome inhibition
regimen designed to target NF-B activation of lung ade-
nocarcinoma limited MPE formation by suppressing the
expression of multiple paracrine mediators of intrapleural
adenocarcinoma dissemination and fluid extravasation,
including TNF and CCL2 [14,15]. Bortezomib treatment
blocked the constitutive and inducible NF-B activation of
mouse lung adenocarcinoma, leading to suppressed MPE-
related inflammation, angiogenesis, and vascular leakiness,
and hence providing for a microenvironment less permis-
sive for MPE development [9-15].
Conclusions
Herein we showed the specific effects of NF-B-tailored
proteasome inhibition against MPE formation by mouse
lung adenocarcinoma. In addition to previous genetic
interventions, the pharmacologic approach employed
herein strengthens the available data that support that
serosal effusion formation, a hallmark of adenocarci-
noma, is governed by expression of paracrine inflamma-
tory and vasoactive mediators. Finally, we showed that
tailored bortezomib treatment is highly effective against
experimental MPE, the mouse analogue of a very
Psallidas et al. Molecular Cancer 2010, 9:56
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Page 9 of 11common, difficult to treat, and debilitating occurrence
in patients with cancer, setting a rational framework
that supports the feasibility of clinical triage of protea-
some inhibition against MPE.
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